Business Context and Reporting Period
This Form 8-K is a Current Report filed by Oncocyte Corporation (not Insight Molecular Diagnostics Inc.) on August 8, 2024. The filing serves to announce the Company's financial results for the three and six months ended June 30, 2024. The detailed results are contained in a press release furnished as Exhibit 99.1, which is incorporated by reference.
Key Financial Metrics
The provided filing text does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are referenced as being detailed in the attached press release (Exhibit 99.1), which is not included in the source text provided for analysis.
Material Changes
The filing text does not provide specific data regarding material changes versus prior comparable periods. It only confirms the issuance of results for the periods ended June 30, 2024.
Guidance, Outlook, and Risks
The filing includes a standard disclaimer stating that the information in Item 2.02 and Exhibit 99.1 is being "furnished" and shall not be deemed "filed" for purposes of Section 18 of the Exchange Act. Consequently, this information is not subject to the liabilities of that section and shall not be deemed incorporated by reference into any other filings unless expressly stated. No specific guidance, outlook, or risk factors are detailed in the text of this 8-K form itself.
Investor Verification Checklist
- Verify the correct registrant name is Oncocyte Corporation (Ticker: OCX), as the request metadata incorrectly listed "Insight Molecular Diagnostics Inc."
- Review Exhibit 99.1 (the press release) for actual financial figures, as the 8-K text only references them.
- Confirm the reporting periods covered are the three and six months ended June 30, 2024.
- Note that the financial data in this filing is "furnished" and not "filed," which may affect its legal standing in future litigation or incorporation by reference.